Jimena Pérez

689 total citations
21 papers, 284 citations indexed

About

Jimena Pérez is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jimena Pérez has authored 21 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jimena Pérez's work include Lung Cancer Treatments and Mutations (8 papers), RNA modifications and cancer (4 papers) and Epigenetics and DNA Methylation (4 papers). Jimena Pérez is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), RNA modifications and cancer (4 papers) and Epigenetics and DNA Methylation (4 papers). Jimena Pérez collaborates with scholars based in United States, Spain and Chile. Jimena Pérez's co-authors include David Sidransky, Jason D. Howard, Christine H. Chung, Elana J. Fertig, Rafael Guerrero‐Preston, Carmen Ili, Ethan Soudry, Michael Considine, Hyunseok Kang and Richard C. Jordan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Jimena Pérez

21 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jimena Pérez United States 9 177 132 97 50 49 21 284
Shengming Xu China 10 170 1.0× 148 1.1× 58 0.6× 15 0.3× 42 0.9× 27 286
Frank Ziemann Germany 8 121 0.7× 113 0.9× 58 0.6× 31 0.6× 57 1.2× 10 259
Yi‐Kan Cheng China 9 243 1.4× 126 1.0× 182 1.9× 16 0.3× 29 0.6× 18 398
Vanessa de Luque Spain 9 135 0.8× 145 1.1× 164 1.7× 11 0.2× 50 1.0× 18 319
Justin Bishop United States 7 167 0.9× 87 0.7× 83 0.9× 11 0.2× 72 1.5× 9 258
Jacqueline E. Mann United States 9 126 0.7× 123 0.9× 93 1.0× 22 0.4× 58 1.2× 20 297
Yae‐Eun Suh United Kingdom 9 188 1.1× 117 0.9× 139 1.4× 24 0.5× 98 2.0× 16 389
Brian C. Willis United States 7 79 0.4× 162 1.2× 52 0.5× 41 0.8× 48 1.0× 9 305
Soheil Yala United States 4 171 1.0× 119 0.9× 41 0.4× 11 0.2× 103 2.1× 6 288
Elke Veltrup Germany 9 95 0.5× 122 0.9× 75 0.8× 11 0.2× 47 1.0× 22 255

Countries citing papers authored by Jimena Pérez

Since Specialization
Citations

This map shows the geographic impact of Jimena Pérez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jimena Pérez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jimena Pérez more than expected).

Fields of papers citing papers by Jimena Pérez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jimena Pérez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jimena Pérez. The network helps show where Jimena Pérez may publish in the future.

Co-authorship network of co-authors of Jimena Pérez

This figure shows the co-authorship network connecting the top 25 collaborators of Jimena Pérez. A scholar is included among the top collaborators of Jimena Pérez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jimena Pérez. Jimena Pérez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ozawa, Hiroyuki, Evgeny Izumchenko, Eugene Makarev, et al.. (2017). SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clinical Cancer Research. 23(17). 5162–5175. 57 indexed citations
2.
Lao, J., Isabel Garau, N. Afonso, et al.. (2016). MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts). Annals of Oncology. 27. vi73–vi73. 1 indexed citations
3.
Fertig, Elana J., Hiroyuki Ozawa, Manjusha Thakar, et al.. (2016). CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. Oncotarget. 7(45). 73845–73864. 8 indexed citations
4.
Cheng, Haixia, Elana J. Fertig, Hiroyuki Ozawa, et al.. (2015). DecreasedSMAD4expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biology & Therapy. 16(8). 1252–1258. 34 indexed citations
5.
Michailidi, Christina, Ethan Soudry, Mariana Brait, et al.. (2014). Genome-Wide and Gene-Specific Epigenomic Platforms for Hepatocellular Carcinoma Biomarker Development Trials. Gastroenterology Research and Practice. 2014. 1–9. 11 indexed citations
6.
Chung, Christine H., Ju‐Whei Lee, Robert J.C. Slebos, et al.. (2014). A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology. 25(11). 2230–2236. 32 indexed citations
7.
Guerrero‐Preston, Rafael, Tal Hadar, Kimberly Laskie Ostrow, et al.. (2014). Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncology Reports. 32(2). 505–512. 44 indexed citations
8.
9.
Gilbert, Jill, Michael J. Schell, Xiuhua Zhao, et al.. (2013). Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 31(15_suppl). 6047–6047. 3 indexed citations
10.
11.
Howard, Jason D., Haixia Cheng, Elena Ratner, et al.. (2013). Abstract 3100: MicroRNA profiling reveals miR-205 upregulation is associated with head and neck squamous cell carcinoma and modulates E2F1 signaling.. Cancer Research. 73(8_Supplement). 3100–3100. 1 indexed citations
12.
Weidhaas, Joanne B., Ju‐Whei Lee, Robbert J.C. Slebos, et al.. (2013). Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.. Journal of Clinical Oncology. 31(15_suppl). 6016–6016. 2 indexed citations
13.
14.
Cheng, Haixia, Elana J. Fertig, Hiroyuki Ozawa, et al.. (2012). Abstract 1889: Smad4 inactivation correlates with EMT and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Research. 72(8_Supplement). 1889–1889. 2 indexed citations
15.
Jiménez, Begoña, et al.. (2011). Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.. Journal of Clinical Oncology. 29(15_suppl). 5594–5594. 3 indexed citations
16.
17.
Jotte, Robert M., Joachim von Pawel, David R. Spigel, et al.. (2011). Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).. Journal of Clinical Oncology. 29(15_suppl). 7000–7000. 40 indexed citations
18.
19.
Barlési, Fabrice, Antonio Pazzola, В. А. Горбунова, et al.. (2010). MAINTENANCE BEVACIZUMAB (BV) WITH OR WITHOUT PEMETREXED (PEM) FOLLOWING FIRST-LINE BV-CISPLATIN (CIS)-PEM IN PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) : PRELIMINARY SAFETY DATA FROM AVAPERL1 (MO22089). Data Archiving and Networked Services (DANS). 21. 144–144. 1 indexed citations
20.
Lacava, J., et al.. (2009). Treatment of early breast cancer (EBC): A long-term follow-up study—GOCS experience. Journal of Clinical Oncology. 27(15_suppl). e11610–e11610. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shengming Xu Breakdown of academic impact, for papers by Frank Ziemann Breakdown of academic impact, for papers by Yi‐Kan Cheng Breakdown of academic impact, for papers by Vanessa de Luque Breakdown of academic impact, for papers by Justin Bishop Breakdown of academic impact, for papers by Jacqueline E. Mann Breakdown of academic impact, for papers by Yae‐Eun Suh Breakdown of academic impact, for papers by Brian C. Willis Breakdown of academic impact, for papers by Soheil Yala Breakdown of academic impact, for papers by Elke Veltrup
Rankless by CCL
2026